Poll results: Will you use biosimilars in your ophthalmic practice?

Poll

Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.

Ophthalmology Times® polled our audience with the following question from September 26, 2022 to October 10, 2022:​ Will you use biosimilars in your ophthalmic practice?

The poll appeared on OphthalmologyTimes.com and was promoted in our e-newsletters during this time. Results show a majority of ophthalmologists plan to use biosimilars in their practice.

37 responses were recorded, in total. Of these:

23% responded, "Yes, I plan to use biosimilars in my practice."

14% responded, "No, I do not plan to use biosimilars in my practice."

.

Recent Videos
This series features 1 KOL.
This series features 1 KOL.
This series features 1 KOL.
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
Video 5 - "Evolving Role of Steroids and Laser In DME"
© 2024 MJH Life Sciences

All rights reserved.